Kaiardl

Inea=Cavatdrnlatne@rnih
Inea=OapprnLcnssdgdlnt
djis=
Xbarnpautdl
Lcnss=NitdljivucsnitsVb
nrenljcjkdlLcnss=Vyrrjcd
hdiahardvntdvas
Hjsnka=
166ek/tn`, > tn`
Graquaily=
JHB\ (nt `ahtdea)
Pjuta=
VJEny nlt `y
dibd`dtdiksdeuctniajus
iaurjincgdrdik tbnt ca
nhs tjsadzura nltdvd
ty. Dtdibd`dts
tba spranh jg sadzura
nltdvdty di tba `rndi.C
avatdrnlatne ds
usahwdtbjtbareahdlntdji
s tjtrant
sadzuras(apdcapsy). Dt
`acjiks tjn lcnss jg hruks
oijwins
nitdljivucsnits.Cavatdrnl
atne enyhalransa tba
iue`ar jgsadzuras n
parsji bns.

Ljitrndihdlntah di p
ntdaitsbyparsaisdtdva
tj tba
hruk.Xba gjccjwdik l
jihdtdjis nraljitrndihdl
ntah wdtb tbds hruk=

niaedn

halransah `cjjh
pcntacats

cjw cavacs jg wbdta
`cjjh laccs

cjw cavacs jg n typa jg
wbdta `cjjh lacclnccah
iautrjpbdcs

psylbjtdl hdsjrhar

sudldhnc tbjukbts

haprassdji

bncculdintdjis

n`ijrenc eniiar jg
wncodik

cjss jg euslca
ljjrhdintdji lbrjidlodhiay
hdsansa (stnka 0 edch,
stnka <Nejharnta, stnka
<@ ejharnta, stnka
8savara)

odhiay hdsansa wdtb
cdoacy rahultdji
diodhiay
guiltdjiNccarkdas=Vyrrjc
dhjia Nincjkuas
LI\=
Nstbaidn,
banhnlba,neiasdn,
nixdaty,
ntnxdn,haprassdji,
hdzzdiass,
bjstdcdty,iarvjusiass,
pnrastbasdn,
pndi,vartdkj,
byparsjeidn,
drrdtn`dcdty,disjeidn,
ljigusdji, gnccs,sahntdji,
n`ijrenc
kndt,diljjrhdintdji.
AAIX=
hdpcjpdn,
ljimuiltdvdtds,
anr pndi, rbdidtds,
sdiusdtds,
insncljikastdji,
pbnryikdtds.
KD=
nijraxdn, vjedtdik,
upparn`hjedinc pndi,
hdnrrban,ljistdpntdji,
knstrjaitardtds.
Baentjcjkdl=
cauojpaidn,iautrjpaidn.
Euslucjsoacatnc=
ialo pndi, mjditsprndi.
Paspdrntjry=
ljukb
\odi=
ljitusdji
Jtbar=
digaltdji, banh
dimury,gcucdoa
syeptjes.
Iursdik Ljisdharntdjis=

Qsa hruk jicy wdtb jtbar
nitdljivucsnits?dt ds ijt
raljeeaihah gjr
ejijtbarnpy.

\adzuras lni jllur
dg hruk ds
stjppahn`ruptcy.
Xnpardik ds raljeeaihah.

Ejidtjr pntdaits gjr sdkis
nih syeptjesjg sjeijcaila
nih gntdkua. \
jeijcailanih nstbaidn jll
urrah
ejst graquaitcywdtbdi
gdrst waaos jg tranteait.

Ejidtjr pntdait lcjsacy gjr
sulb nhvarsaranltdjis ns
hdzzdiass, wbdlb eny
canh tjgnccs.

Hdsljitdiua nih ijtdgy
praslrd`ar gjr sdkis ni
h syeptjes jg ninpbyc
nxds(bypjtaisdji, bdvas,
rnsb, nih
raspdrntjryhdstrass) nih
jg nikdjahaen (swaccdik
jg gnla, cdps, ejutb,
ayas, tjikua, tbrjnt,
nihgaat).
GENERIC NAME,
BRAND NAME,
CLASSIFICATION
Prescribed and
Recommended
dosage, frequency,
route of
administration
Mechanism of
Action
Indication Contraindication Adverse Reaction
Nursing
Responsibilities
Generic Name:
Piperacillin sodium–
tazobactam sodium
Brand Name:
Piptaz
Classification:
Extended-spectrum
penicillins–beta
lactamase inhibitors,
Antibiotics
Prescribed dosage:
600 mg IV drip q 8°
Recommended dosage:
200-300 mg/kg/day
IV/IM divided q4-6hr
Inhibits cell-wall
synthesis during
bacterial
multiplication.
Route: IV
Onset: Immediate
Peak: Immediate
Duration: Unknown
Half-life: About 0.7
to 1.5 hours.
Moderate to severe
infections from
piperacillin-resistant,
piperacillin-tazobactam–
susceptible, beta
lactamase–producing
strains of microorganisms
in appendicitis
(complicated by rupture
or abscess) and peritonitis
Appendicitis, peritonitis
Moderate to severe
nosocomial pneumonia
caused by piperacillin
resistant, beta-lactamase–
producing strains of S.
aureus or by piperacillin
tazobactam–susceptible
Acinetobacter baumannii,
H. influenzae, Klebsiella
pneumoniae, and
Pseudomonas aeruginosa
Contraindicated in
patients
hypersensitive to
drugs, other
penicillin
cephalosporins, or
beta-lactamase
inhibitors.
CNS: headache,
insomnia, fever, seizures,
agitation, anxiety,
dizziness, pain. CV:
arrhythmia, chest pain,
edema, HTN,
tachycardia. EENT:
rhinitis. GI: diarrhea,
constipation, nausea,
pseudomembranous
colitis, abdominal pain,
dyspepsia, stool changes,
vomiting, oral
candidiasis. GU:
candidiasis, interstitial
nephritis. Hematologic:
leukopenia, neutropenia,
thrombocytopenia,
anemia, eosinophilia.
Respiratory: dyspnea.
Skin: pruritus, rash.
Other: anaphylaxis,
hypersensitivity
reactions, inflammation,
phlebitis at IV site.
Monitor patient for
diarrhea and initiate
therapeutic measures
as needed.
Alternative treatments
should be considered;
if alternative treatment
options are inadequate
or unavailable, monitor
renal function during
therapy.
Serious skin reactions
can occur. If rash
develops, monitor
patient closely and
discontinue if lesion
progresses.
Drug contains 2.84
mEq (65 mg) sodium
per gram of
piperacillin. Monitor
patient’s sodium intake
and electrolyte levels.
Ejidtjr rainc guiltdji
ns nluta odhiaydimury
bns `aai rapjrtah.

Lcjsacy ejidtjr gjr
lbnikas di
`abnvdjr dihdlntdik
psylbjsds jr wjrsaidik
jg sudldhnc tbjukbts
jr `abnvdjr jr haprass
dji.
>